Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone effect on Methylphenidate Abuse Potential
NCT03769064Phase 1Completed
- Sponsor
- Avekshan
- Start
- Mar 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of methylphenidate + naltrexone in attention deficit hyperactivity disorder (ADHD) (4 arms), sponsored by Avekshan. Primary endpoint: Maximum Effect of Naltrexone at 70 days. Started Mar 2018; status: completed.
02
Drugs
methylphenidate + naltrexone
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03769064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769064.